RecruitingPhase 1Phase 2NCT06219018

Effect of Honey For CIN II

The Effect of Medical Grade Honey (L-Mesitran) for Cervical Intraepithelial Neoplasia-II


Sponsor

Zuyderland Medisch Centrum

Enrollment

60 participants

Start Date

Dec 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether applying honey directly to the cervix can help clear cervical cell changes (CIN II — a moderate abnormality) that are at risk of becoming cervical cancer. CIN II often resolves on its own, and this trial explores whether honey might support that natural healing process. **You may be eligible if...** - You are a woman aged 18–40 - You have been diagnosed with CIN II (confirmed by biopsy) - You have a confirmed high-risk HPV infection - You understand sufficient Dutch to follow the study instructions **You may NOT be eligible if...** - You also have abnormal glandular cells (AIS) on your cervix - Your HPV test came back negative on cytology - You have an immune system condition (such as HIV or CVID) or are on immunosuppressant medication - You have a history of cervical cancer or have been previously treated for CIN (e.g., LLETZ procedure) - You are pregnant or plan to become pregnant during the study - You are allergic to honey Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMedical grade honey formulation (MGH) (L-Mesitran®)

Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.


Locations(2)

Zuyderland MC

Heerlen, Limburg, Netherlands

Maastricht University Medical Centre+

Maastricht, Limburg, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06219018